AstraZeneca may have provided incomplete efficacy data from the latest Covid-19 trial-NIAID, Health News, ET HealthWorld

The National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday that British pharmaceutical company AstraZeneca Plc may have provided an incomplete view of the efficacy data of the Covid-19 vaccine from a large US trial. Stated.

AstraZeneca said yesterday that the Covid-19 vaccine developed at Oxford University is 79% effective in preventing symptomatological disorders in large-scale trials in the United States, Chile and Peru.

“DSMB expressed concern that AstraZeneca may have contained outdated information from its trials, which may have provided an incomplete view of the validity data,” the U.S. agency said. Mentioned and stated the Independent Data Safety Monitoring Commission (DSMB).

“We urge the company to work with DSMB to review the validity data and publish the most accurate and up-to-date validity data as soon as possible.”

The request questioned the company’s plans to seek a US emergency use authorization for the vaccine within the next few weeks.

According to NIAID, which is part of the National Institute of Allergy, approval and guidelines for vaccine use in the United States are decided by the Food and Drug Administration and the Centers for Disease Control and Prevention after a thorough review of the data by an independent advisory board. Will be done. health.

AstraZeneca’s shot, which was welcomed as a milestone in the fight against the Covid-19 pandemic that emerged as a vaccine candidate last year, has been plagued by doubts about its efficacy, dosing regimen, and possible side effects.

Back to top button